Brief: Corline Biomedical Chooses Abzena As Partner For Clinical Trial Phase 2
Feb 3 (Reuters) - Corline Biomedical AB CLBIO.ST :
* CHOOSES ENGLISH ABZENA LTD. AS PARTNER FOR MANUFACTURING
OF DRUG
SUBSTANCE FOR CLINICAL TRIAL PHASE 2
* COLLABORATION INCLUDES DELIVERY FOR CLINICAL TRIALS
* LONG-TERM STRATEGY IS FOR ABZENA TO BE CORLINE'S FUTURE
COMMERCIAL SUPPLIER
Source text for Eikon: ID:nGNEcdFjCG
Further company coverage: CLBIO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Corline Biomedical AB
See all newsBrief: Corline Biomedical Expectes Positive EBITDA In 2027
Brief: Corline Biomedical: Canada To Grant Kardium Up To C$31.25 Mln For Manufacturing Capacity Expansion
Brief: Corline Biomedical Q2 Net Sales Amount To SEK 4.7 Million
Brief: Corline Biomedical Partner Kardium Receives Approval For Globe Pulsed Field System In Canada
Brief: Corline Biomedical Q1 Result After Financial Items At SEK -2.5 Mln